Nucleome Therapeutics Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $6.43M
Latest Deal Amount
  • Investors
  • 1

Nucleome Therapeutics General Information

Description

Developer of a nucleome decoding platform intended to unlock the non-coding genome for human health. The company's platform uses novel molecular biology techniques that define the 3D structure of the genome and computational genomics powered by machine learning to identify disease affected pathways, enabling professionals to get genetically guided therapeutic to provide improved patients outcome.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • BioEscalator The Innovation Building
  • The Old Road Campus, Roosevelt Drive, Headington
  • Oxford OX3 7FZ
  • England, United Kingdom
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nucleome Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 08-Aug-2019 $6.43M 00.000 000.00 Completed Startup
To view Nucleome Therapeutics’s complete valuation and funding history, request access »

Nucleome Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Nucleome Therapeutics’s complete cap table history, request access »

Nucleome Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Danuta Jeziorska Ph.D Co-Founder, Chief Executive Officer & Board Member
James Hughes Co-Founder & Board Member
James Davies Co-Founder, Board Member & Board Observer
To view Nucleome Therapeutics’s complete executive team members history, request access »

Nucleome Therapeutics Board Members (5)

Name Representing Role Since
Danuta Jeziorska Ph.D Nucleome Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
James Davies Nucleome Therapeutics Co-Founder, Board Member & Board Observer 000 0000
James Hughes Nucleome Therapeutics Co-Founder & Board Member 000 0000
Lachlan MacKinnon Oxford Sciences Innovation Board Member 000 0000
Matthew Carpenter Ph.D Self Board Observer 000 0000
To view Nucleome Therapeutics’s complete board members history, request access »

Nucleome Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nucleome Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Oxford Sciences Innovation Venture Capital Minority 000 0000 000000 0
To view Nucleome Therapeutics’s complete investors history, request access »